Presentation Summary : The Role of SGLT-2 Inhibitors in the Management of Patients with Type 2 Diabetes Lawrence Blonde, MD Director, Ochsner Diabetes Clinical Research Unit,
Source : http://www.nysafp.org/images/uploads/misc/1326909268_SGLT-2%20powerpoint%20AFP.ppt
Presentation Summary : * Treatment of Hypoglycemia: AACE/ACE ... Exenatide XR Bydureon Liraglutide Victoza SGLT2 inhibitors Increase urinary excretion of glucose Canagliflozin ...
Source : http://outpatient.aace.com/sites/all/files/T2DM_S5_Treatment_041813.ppt
Presentation Summary : Role of the Kidney in T2DM - WorldWIDE Diabetes
Source : http://www.worldwidediabetes.org/wp-content/downloads/role-of-the-kidney.ppt
Presentation Summary : Model-Based Meta-Analysis of HbA1c, Weight, and FPG in Type 2 Diabetes: Focus on SGLT2 inhibitors William S. Denney and Gianluca Nucci Pfizer Global R&D, Groton/New ...
Source : http://www.go-acop.org/sites/default/files/webform/posters/Denney-SGLT-2%20Poster-ACoP%202011.ppt
Presentation Summary : Hyperglycemia in Type 2 Diabetes Sodium Glucose Cotransporters Location of Sodium Glucose Cotransporters in the Kidney SGLT2 Inhibitors Rationale for SGLT2 ...
Source : http://img.medscape.com/images/32761/779655_slides.ppt
Presentation Summary : Rationale for SGLT2 Inhibitors. The SGLT2 is a glucose transporter responsible for 90% of glucose reabsorption. Selective SGLT2 inhibitors could reduce blood glucose ...
Source : http://www.inosteo.org/UserFiles/File/PowerPoint/2012%20IOA%20Annual%20Convention/Saturday/Advances%20in%20Type%202%20Diabetes.Novel%20Agents%20that%20Target%20the%20Kidney.Freeman.pptx
Presentation Summary : Several selective SGLT2 inhibitors ... Assuming the SGLT2 transporter is ... Confidence in decision making greatly enhanced by systems pharmacology resulting ...
Source : http://www.go-acop.org/sites/default/files/webform/posters/Nucci-SGLT2i-Poster-ACoP-2011.ppt
Presentation Summary : SGLT2 Inhibitors Lower Renal Threshold for Glucose Excretion. SGLT2 Inhibitors. Blood Pressure Effects of SGLT2 Inhibitors. SGLT2 Adverse Effects (Well Tolerated)
Source : http://img.medscape.com/images/829/831/829831_slides.pptx
Presentation Summary : Sodium-Glucose-Cotransporter-2 (SGLT2) Inhibitors: The Latest Class of Oral Agents. Canagliflozin and Dapagliflozin are the first FAD approved SGLT-2 In.
Source : http://adc2014.com/presentations/Osama-Hamdy/001.pptx
Presentation Summary : DPP-4 inhibitors. Highly specific, block DPP-4 to increase endogenous GLP-1. ... (SGLT2) inhibitors. Drugs Targeting Non-Insulin-Dependant Pathways. Hepatic targets.
Source : http://www.segageriatrics.com/wp/wp-content/uploads/2011/09/New-DMII-Treatments.pptx
Presentation Summary : Objectives. Pharmacists will be able to: Describe SGLT2 inhibitors. Compare available SGLT-2 inhibitors. Identifyideal candidates for SGLT2 inhibitors
Source : http://www.drsamrotation.com/uploads/1/9/8/6/19863509/jardiance_presesentation_rahul.pptx
Presentation Summary : Review the role of the kidney in the maintenance of normal glucose homeostasis. 6. Discuss the role of the SGLT2 inhibitors in the treatment of Type 2 DM. 7. Define ...
Source : http://www.sanap.org/Diabetes_flyer_2014_registration_form.ppt
Presentation Summary : Distinguish the unique differences between new SGLT2 inhibitors and discuss the clinical implications of these differences on appropriate patient selection .
Source : http://www.arkansasafp.org/wp-content/uploads/Niyaz-Gosmanov-M.D..pptx
Presentation Summary : ... a relatively benign condition in humans Selective SGLT2 inhibitors have a novel & unique mechanism of action reducing blood glucose levels by increasing renal ...
Source : http://www.osteopathic.org/inside-aoa/events/omed/omed-presentations/Documents/2013%20OMED%20Presentations/cleveland-clinic-skugor-oral-antidiabetic-medications.ppt
Presentation Summary : ... Antiplatelet therapy Annual screening of complications Diabetic education New drugs in diabetes mellitus Selective SGLT2 Inhibitors Dapagliflozin ...
Source : http://www.tlaa.org/2012/timac_rename.php?timac_pdf_id=11
Presentation Summary : SGLT2 inhibitors reduce renal glucose reabsorption. SGLT2 inhibitor. SGLT2 : Potential Role. DM2 at any level . Monotherapy in metformin intolerance.
Source : http://www.ruraldoctors.ie/wp-content/uploads/2014/03/Dr.MC-Durkan-Whats-New-Diabetes.pptx
Presentation Summary : New mechanism of action - SGLT2 inhibition. Dose related A1c reductions studied as monotherapy and in combination with SFU, ... Mechanism of action – SGLT2 inhibitors.
Source : http://metrohealth.net/wp-content/uploads/2012/01/Wolfe-Winter-Update-2014-DM1.pptx
Presentation Summary : SGLT2 inhibitors are a new subclass of the non-insulin DM drugs class. Efficacy is limited to 8 clinical trials, showing moderate decreases in A1c from baseline ...
Source : http://pec.ha.osd.mil/files/PECwebcast_Sep%202013%20Final.pptx
Presentation Summary : ... Dr. Howard Verrico, Sirona Biochem’s first transaction was to acquire an exclusive global license to TFChem’s SGLT2 Inhibitor ...
Source : http://www.sironabiochem.com/wp-content/uploads/2014/02/SBM-Introduction-01292014.pptx
Presentation Summary : SGLT2 Inhibitors. Dapagliflozin. Blood glucose monitoring may be required in patients: with acute illness. up to 7 days post-surgery. co-prescribed steroids .
Source : http://www.westsuffolkccg.nhs.uk/wp-content/uploads/2014/02/WSCCG-BGTS-Presentation-FINAL-Jan2014-FOR-WEBSITE.pptx
Presentation Summary : SGLT2 Inhibitors. SGLT2, sodium-glucose cotransporter 2. DeFronzo RA, et al. Diabetes . Obes. Metab. 2012;14:5-14. Glucose Controlwith SGLT2 Inhibitors.
Source : http://outpatient.aace.com/sites/all/files/T2DM-S5-New-Antidiabetic-Therapies-080614.pptx
Presentation Summary : Systematic review and meta-analysis of SGLT2 inhibitors in patients with T2DM. SGLT2-i have a favourable effect on HbA1c, systolic blood pressure weight and .
Source : http://www.gastaldicongressi.it/attach/relazioni/2013/05.%20Gentile%20-%20Ipoglicemia.pptx
Presentation Summary : SGLT2 Inhibitors No evidence of cancer risk DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon like peptide-1; MTC, medullary thyroid carcinoma; SGLT2, ...
Source : https://www.aace.com/files/diabetes-and-cancer-consensus-statement.pptx